标题：雌激素受体、孕激素受体、p53及Ki-67在子宫内膜癌组织中的表达及其与临床病理特征的关系

      作者：王娟 1，李军 2，郭灿灿 1    (西宁市第二人民医院妇科 1、检验科 2，青海 西宁 810000)

      卷次： 2017年28卷2期

      【摘要】 目的 观察雌激素受体(ER)、孕激素受体(PR)、p53及Ki-67在子宫内膜癌组织中的表达，并探讨其与临床病理特征的关系。方法 选取2015年2月至2016年2月我院妇科收治的子宫内膜癌患者156例为观察组，选取同期正常子宫内膜组织70例为对照组，应用免疫组化分析法检测两组患者组织中ER、PR、p53及Ki-67的表达情况，并分析ER、PR、p53及Ki-67的表达与临床病理的关系。结果 观察组患者的ER和PR表达阳性率分别为44.9%和41.0%，明显低于对照组的91.4%和94.3%，p53和Ki-67表达阳性率分别为86.5%和68.6%，明显高于对照组的0和0，差异均具有统计学意义(P<0.05)；Ⅲ~Ⅳ期患者的ER和PR表达阳性率分别为11.1%和18.5%，明显低于Ⅰ期和Ⅱ期患者，p53和Ki-67表达阳性率分别为 100.0%和 98.1%，明显高于 I期和 II期患者，差异均具有统计学意义(P<0.05)；组织分级G3级患者的ER和PR表达阳性率分别为17.6%和17.6%，明显低于G1级和G2级，p53和Ki-67表达阳性率分别为100.0%和82.4%，明显高于G1级和G2级，差异均具有统计学意义(P<0.05)；腺癌和非腺癌患者的ER、PR和 p53表达阳性率比较差异均无统计学意义(P>0.05)，腺癌Ki-67表达阳性率为 84.5%，明显高于非腺癌的42.4%，差异有统计学意义(P<0.05)。结论 ER、PR表达缺失和p53、Ki-67表达增高与子宫内膜癌有关，且与临床病理存在较大关系。
      【关键词】 雌激素受体；孕激素受体；p53；Ki-67；子宫内膜癌
      【中图分类号】 R737.33 【文献标识码】 A 【文章编号】 1003—6350（2017）02—0211—03

Expression of estrogen receptor, progesterone receptor, p53 and Ki-67 in endometrial carcinoma and theirrelationship with clinical pathological characteristics.
WANG Juan 1, LI Jun 2, GUO Can-can 1. 1. Department ofGynecology 1, Department of Clinical Laboratory 2, the Second People's Hospital of Xining City, Xining 810000, Qinghai,CHINA
【Abstract】 Objective To observe the expression of estrogen receptor (ER), progesterone receptor (PR), p53 andKi-67 in endometrial carcinoma, and to explore their relationship with clinical pathological characteristics. Methods Atotal of 156 patients with endometrial carcinoma, who admitted to Department of Gynecology of our hospital from Feb-ruary 2015 to February 2016, were selected as the observation group. At the same time, 70 patients with normal endome-trial tissue were chosen as the control group. The expressions of ER, PR, p53 and Ki-67 in two groups were detected byimmunohistochemistry, and the relationship between the expressions of ER, PR, p53 and Ki-67 and clinical pathologywere analyzed. Results The positive rates of ER and PR expression in the observation group were respectively 44.9%and 41.0%, which were significantly lower than 91.4% and 94.3% in the control group (P<0.05); the positive rates ofp53 and Ki-67 expression were respectively 86.5% and 68.6%, which were significantly higher than 0 and 0 in the con-trol group (P<0.05). The positive rates of ER and PR expression in the period of Ⅲ~Ⅳ were respectively 11.1% and18.5%, which were significantly lower than those in the period of Ⅰ and Ⅱ (P<0.05); the positive rates of p53 and ex-pression Ki-67 were respectively 100.0% and 98.1%, which were significantly higher than those in the period ofⅠ andⅡ (P<0.05). The positive rates of ER and PR expression in G3 grade patients were respectively 17.6% and 17.6%, whichwere significantly lower than those in G1 and G2 grade patients (P<0.05); the positive rates of p53 and Ki-67 expressionwere respectively 100.0% and 82.4%, which were significantly higher than those in G1 and G2 grade patients (P<0.05).There was no significant difference in the positive rates of ER, PR and p53 expression between the patients with adeno-carcinoma and non-adenocarcinoma (P>0.05). The positive rate of Ki-67 expression in adenocarcinoma was 84.5% ,which was significantly higher than 42.4%in non-adenocarcinoma (P<0.05). Conclusion The deletion expression ofER and PR and increased expression of Ki-67 and p53 are associated with endometrial cancer, and there is a significantrelationship with clinical pathology.
      【Key words】 Estrogen receptor (ER); Progesterone receptor (PR); p53; Ki-67; Endometrial carcinoma·论 著·doi:10.3969/j.issn.1003-6350.2017.02.013